USA flag logo/image

An Official Website of the United States Government

Novel High Affinity VEGF Analogs for Imaging Thyroid Cancer

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R44CA171352
Solicitation Year:
2013
Solicitation Topic Code:
NCI
Solicitation Number:
PA12-088
Small Business Information
TROPHOGEN, INC.
9714 Medical Center Dr. ROCKVILLE, MD -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Novel High Affinity VEGF Analogs for Imaging Thyroid Cancer
Agency: HHS
Contract: 1R44CA171352-01A1
Award Amount: $283,958.00
 

Abstract:

DESCRIPTION (provided by applicant): Thyroid cancer of follicular origin is the most common malignancy of endocrine tissues, disproportionally affecting women, and is one of the few cancers greatly increasing in incidence and prevalence for unknown reasonsnot solely attributable to improved diagnosis. Most patients require lifelong diagnostic surveillance with radioiodine imaging to detect residual and recurrent tumor requiring subsequent therapy with 131I. One of the PIs co-invented and co-developed Genzyme's recombinant human TSH (Thyrogen), currently approved for enhancing diagnostic imaging with radioiodine and for stimulation of the thyroid cancer serum marker, thyroglobulin (TG). However there is currently no optimal method to image the greatly increasing number of more aggressive cancers causing major morbidity and mortality, detected by increased serum Tg, but which have lost the ability to concentrate radioiodine because of decreased expression of the Na/I symporter. Nor is there any diagnostic method to predict which tumors may respond to increasingly important anti-angiogenic therapy for these usually highly angiogenic tumors. The two PIs have invented completely novel, patented methods to design and produce much higher affinity and longer acting analogs of VEGF which can be used in novel, targeted imaging of such tumors to the VEGFR2 receptor in both the stromal vascular endothelium and in tumor epithelium, as supported by extensive and compelling preliminary data. Two approaches of targeted imaging will be compared: a direct optimized 99mTcm labeling method of such soluble VEGF analogs and another method using novel pegylated and VEGF analog targeted stealth nanoparticles which can selectively transverse the highly fenestrated, leaky tumor vessels of angiogenic tumor vessels but not normal vessels. In Phase 1 of this SBIR fast track the PIs will: (1) Develop higher affinity and longer acting hVEGF analogs by lysine and arginine scanning mutagenesis of selected loops in both poles of the dimeric ligand without and with introduction of a novel neoglycosylation site adding two complex, sialylated carbohydrate chains; assessing binding of each analog to VEGFR2 and bioactivity in the stimulation of human vascular endothelial cell (HUVEC) proliferation;produce and purify 5-10 mg amounts of the final 3 glycosylated and optimally sialylated analogs in CHO cells in roller bottles; (2) Develop novel pegylated polymeric stealth nanoparticles targeted by covalently coupled high affinity VEGF ligand and labeled with coupled radionuclides to high specific activity; (3) Assess in vitro binding and internalization of as wellas in vivo pharmacokinetic properties of VEGF analogs directly coupled to 99mTc or 125I compared to VEGF analog-targeted labeled nanoparticles. In Phase 2 the PIs will: (1) Produce and purify large amounts (50-200 mg) of the final 2 selected VEGF analog targeting candidates in a large mammalian cell bioreactor; (2) Greatly extend Phase 1 in vivo and ex vivo imaging results by further optimizingimaging sensitivity and specificity; (3) Perform parallel quantitativ organ uptake studies with labeled VEGF analogs; (4) Make the final selection of the specific analog, radionuclide and direct labeling versus indirect nanoparticle labeling method to bring forward for commercialization based on multiple criteria. These completely novel methods for earlier detection and localization of the increasing numbers of aggressive thyroid cancers should lead to earlier and more personalized therapy predicting whichpatients will most benefit from increasingly important but potentially toxic anti-angiogenic therapy. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Thyroid cancer of follicular origin is the most common malignancy of endocrine tissues, and is increasing in incidence and prevalence for unknown reasons. Most patients require lifelong diagnostic surveillance with radio-iodine imaging to detect recurrent tumor and subsequent therapy with 131I. However this approach only is applicable to differentiated thyroid cancers and there is currently no specific method of cancer imaging or any optimal method to treat more aggressive, less differentiated cancers or those which have lost differentiation with time or repeated therapy. The two PI's have inventeda completely novel and patented method to design and produce much higher affinity analogs of VEGF which can be used in both the targeted imaging and therapy of thyroid. The targeted imaging will be achieved by an optimized labeling method of such novel VEGF analogs while the therapy will for the very first time utilize the power of nanotechnology to specifically target the cancer cells and not normal cells with tiny, VEGF analog-coated lipid particles. These particles will be engineered to contain radio-iodine or other imaging agent used as a prelude to subsequent targeted thyroid cancer therapy. These completely novel and much improved methods for early detection of thyroid cancer followed by much improved and less toxic targeted therapy should lead to better outcomes, including both survival and quality of life.

Principal Investigator:

Bruce D. Weintraub
(301) 838-1936
bweintraub@trophogen.com

Business Contact:

Bruce D. Weintraub
(301) 838-1936
bweintraub@trophogen.com
Small Business Information at Submission:

TROPHOGEN, INC.
9714 Medical Center Dr. ROCKVILLE, MD -

EIN/Tax ID: 152232768
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No